Please enable JavaScript or talk to your local administrator to get JavaScript enabled.


Analysis of the expression and inhibition of indoleamine 2,3-dioxygenase (IDO) in the epithelial-mesenchymal transition in bladder cancer

Funder: São Paulo Research Foundation

Funding period
Funding amount
Bladder cancer (CB) is the seventh most common cancer in men, noting that noninvasive tumors account for the largest number of cases. Transurethral resection of the bladder tumor (RRTV) associated with Bacilo Calmette-Guérin (BCG) immunotherapy is the most effective treatment and prophylaxis for non-muscle invasive tumors. Treatment with BCG is considered the best therapy, however, approximately 30 to 40% of patients do not respond to this therapy, which may favor the progression of the disease to invasive forms. The use of BCG induces the release of interferon-gamma, an indoleamine-2,3-dioxygenase (IDO) inducer, and IDO is likely to be related to the events triggered by this therapy. IDO, expressed in the placenta and lymphoid organs, plays an immunomodulatory role, which guarantees the tumor escape in several types of cancer. It is known that in the intensification of the epithelial-mesenchymal transition (TEM) mediated by TGF-beta, there is a change in the IDO, the objective of this work is to analyze the expression of these two markers, correlating them with the TEM markers with and without treatment with BCG. In addition, to verify if inhibition of IDO influences TEM in BC with and without BCG treatment. The orthotopic murine CB model will be used. Tumor samples will be collected for immunohistochemical evaluation of the expression of IDO, TGF-beta and TEM markers, as well as by means of real-time PCR. Identifying the participation of IDO in TEM, as well as the pathophysiology of CB, may help the development of new prognostic, diagnostic and therapeutic tools.
Similar projects All >
Sorted by: Start Date
Project list item
Intravesical delivery of an Fc-enhanced CD40 agonist antibody for the treatment of bladder cancer

Bladder Cancer Advocacy Network to Jeffrey Ravetch, David Knorr

USD 300,000
2020 - 2022
Project list item
CD40 agonism for the treatment of bladder cancer

National Cancer Institute to CHRISTOPHER STUART GARRIS

USD 64,554
2020 - 2023
Project list item
Analysis of the effect of IDO inhibition on activation of the aryl hydrocarbon receptor pathway in bladder cancer

São Paulo Research Foundation to Humberto Dellê

2020 - 2021
Project list item
[Studies on a novel immunotherapy for bladder cancer by NAD+] - Original in Japanese

Japan Society for the Promotion of Science to 博史 上原, Kazumasa Komua, Haruhito AZUMA

USD 39,508
2019 - 2024
Project list item
Combatting Bladder Cancer by Inducing Epithelial Turnover

National Cancer Institute to SOMAN N ABRAHAM

USD 372,404
2019 - 2021



    1112 Oncology and Carcinogenesis

  • RCDC


  • RCDC

    Urologic Diseases



  • Health Research Areas


  • Broad Research Areas

    Clinical Medicine and Science